Notably, with the augmented GSK3β activity in the animal models with diabetes or obesity, the level of S255 phosphorylation is significantly elevated, further boosting the detrimental effects of increased MG53 expression under these pathological conditions. Here, GSK3B is linked to obesity disorder.